Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Biosimilar Market Outlook 2022 - Entry of Biosimilars in the US Market & Rising Incidences of Chronic Diseases - Research and Markets

Research and Markets
Posted on: 13 Sep 16

Research and Markets has announced the addition of the "Global Biosimilar Market Outlook 2022" report to their offering.

The global biosimilars market is anticipated to witness a high double digit growth during 2016-2022

This report provides a detailed analysis of the current and future market scenario of the global biosimilars market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global biosimilars market.

A biosimilar is a biologic product that is similar to a regulatory body approved reference product, and has no clinically meaningful differences in terms of safety and effectiveness from that reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry. Furthermore, the recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field.

The global biosimilars market has been segmented on the basis of type of product. The major types of biosimilars present in the market include monoclonal antibodies, erythropoietin, insulin, G-CSF, HGH, and interferon amongst others. The report also highlights the various biosimilar drugs available in the market, and the biosimilars currently in various phases of clinical trials.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Global Biosimilars Market Outlook 2022

4. Market Dynamics

4.1 Drivers

4.1.1 Growing Geriatric Population

4.1.2 Entry of Biosimilars in the US Market

4.1.3 Ability to Curb Healthcare Cost

4.1.4 Rising Incidences of Chronic Diseases

4.1.5 Government Initiatives

4.2 Challenges

4.2.1 Regulatory Issues

4.2.2 Greater Litigation Risk

4.2.3 Lack of Standardized Manufacturing Process

4.3 Opportunities

4.3.1 Emerging Markets - Area of Opportunities for Biosimilars

4.3.2 Patent Expiry of Blockbuster Biologics

5. Market Segmentation by Product Type

5.1 Erythropoietin (EPO)

5.2 Human Growth Hormone (HGH)

5.3 Granulocyte- Colony Stimulating Factor (G-CSF)

5.4 Monoclonal Antibody (mAb)

5.5 Insulin

5.6 Interferon (IFN)

5.7 Others

6. Market Segmentation by Geography

7. Market Segmentation by Applications

7.1 Oncology

7.2 Blood Disorders

7.3 Others

8. Market Trends and Developments

8.1 Development of Modular Biosimilar Plants

8.2 Biosimilars in Oncology

9. Mergers and Acquisitions

10. Porter's Five Forces Analysis

11. Competitive Landscape

11.1 Market Share of Major Players

11.2 Company Profiles

12. Future Outlook

Companies Mentioned

  • Amgen Inc.
  • Biocad
  • Biocon
  • Celltrion Inc.
  • Dong-A Socio Group
  • Intas Pharmaceuticals Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH - A Novartis Company
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit

Related Topics: Biosimilars and Biosuperiors

View source version on

Business Wire

Last updated on: 13/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.